Every material Form 8-K BioNexus Gene Lab Corp has filed with the SEC since June 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 5, 2026, BioNexus Gene Lab Corp. agreed to an exclusive Malaysian healthcare licence to Ruanyun Edai Technology's CogniAI document-intelligence platform, with closing still pending. The company will issue a total of 560,000 common shares, about 16.0% of its outstanding shares after issuance, with no cash payment, which shareholders would bear as dilution. The filing states that BioNexus has not been awarded any government contract and that closing depends on technology acceptance, due diligence and approvals.
Share consideration: 410,000 shares for a stated US$3.5 million licence fee, plus 150,000 shares for 500,000 RYET ordinary shares, totaling 560,000 shares, or about 16.0% of outstanding common shares after issuance.
Royalty: RYET receives 10% of defined technology receipts actually collected, with no minimum royalty or annual platform fee.
Closing: either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
Government work: BioNexus has not been awarded any government contract, and any public-sector work would depend on government procurement.
BioNexus issued a press release describing progress toward commercializing the VitaGuard MRD platform in Southeast Asia following a working visit to Tongshu Gene facilities in China. The filing contains no financial results, new agreements or financial commitments, and it states that no definitive agreement has been executed for markets outside Southeast Asia.
Visit to Tongshu Gene facilities in Shanghai and Changzhou, China, led by Fidelion Chief Commercial Officer Dr. Muthu Meyyappan
Company continues to target initial deployment in select Southeast Asian medical hubs during 2026, subject to work and approvals
Work is underway in Malaysia and Singapore; Fidelion is in discussions with prospective partners outside Southeast Asia, with no definitive agreement executed
BioNexus owns approximately 15% of Fidelion Diagnostics
BioNexus Gene Lab Corp. furnished a May 29, 2026 press release describing its participation in the 2026 China-Malaysia Economic Cooperation Outlook Forum held May 21, 2026 in Kuala Lumpur. The company's CEO, Sam Tan, urged Malaysia-China biotechnology cooperation to move beyond trade into co-development. The filing contains no financial results, guidance, or transaction terms, so it gives shareholders no new financial measures.
Press release dated May 29, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
Participation in the 2026 China-Malaysia Economic Cooperation Outlook Forum on May 21, 2026 at the Mandarin Oriental Hotel, Kuala Lumpur
Release cites its Fidelion Diagnostics Pte. Ltd. and VitaGuard MRD platform as an example of its cross-border commercialization model
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BioNexus Gene Lab Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →